R2 Technology PMA submission for ImageChecker mammogram analyzer expected by year end, firm says.
This article was originally published in The Gray Sheet
Executive SummaryR2 TECHNOLOGY IMAGECHECKER MAMMOGRAM ANALYZER PMA SUBMISSION is expected by "fall to early winter," James Pell, R2's president and CEO, told investors at the March 6 UBS Securities women's health conference in New York City. The system, intended to serve as a second reader of mammograms following initial review by a radiologist, could "significantly" reduce the number of detectable breast cancers missed during routine screening, Pell said.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.